Biopharma News

Cytovance Biologics and Selexys Pharmaceuticals enter an agreement for development of clinical trial materials.

Kymab receives $40 million investment for clinical development of antibody therapeutics.

FDA issues complete response letter for Novartis' RLX030 for acute heart failure.

Advanced Scientifics and Chemic Laboratories enter a three-year joint cooperation agreement to collaborate on product development projects.

AstraZeneca will collaborate with the Medical Research Council Laboratory of Molecular Biology to fund a range of pre-clinical research projects.

KBI Biopharma acquires Merck's microbial process development and manufacturing operations in Colorado.

Shire expands rare disease portfolio with acquisition of Lumena Pharmaceuticals.

Cumberland Pharmaceuticals and Gloria Pharmaceuticals invest $1 million each in Cumberland Emerging Technologies.

Boehringer Ingelheim and Connexios Life Sciences announce global research collaboration agreement for AMPK agonists.

Allergy Therapeutics announced that its Worthing facility has received its Certificate of GMP Compliance following recent inspection by the MHRA.

BMS acquisition of iPierian advances BMS' pursuit of therapeutics for genetically defined diseases.

Bristol-Myers Squibb and Samsung BioLogics expand their manufacturing agreement to cover biologic medicines.

Lilly1s Cyramza is the first FDA-approved treatment for advanced gastric cancer after prior chemotherapy.

Aastrom Biosciences will acquire Sanofi's CTRM business for $6.5 million.

Novartis receives FDA breakthrough therapy designation for Bexsero, a meningitis B vaccine.

ThioBridge linker technology to attach different payloads to a range of antibodies

uniQure appoints a new COO and vice president, Medical affairs.

Eli Lilly will present early-stage data regarding cancer therapies at AACR 2014.

Sun Pharma acquisition of Ranbaxy Laboratories will create the fifth-largest specialty generics company in the world.

Sun Pharma acquisition of Ranbaxy Laboratories will create the fifth-largest specialty generics company in the world.

European scientists have discovered a method to improve the efficiency of the pharmaceutical production through plant biotechnology.

New research finds that recurrent head and neck tumors have gene mutations that could be vulnerable to the cancer drug dasatinib.

Immunovaccine reports enhanced cancer vaccine combination therapies at 2014 AACR Annual Meeting.

Sanofi and Genzyme to resubmit FDA application for approval of Lemtrada, for the treatment of relapsing forms of multiple sclerosis.

Novartis delivers 2 million treatments of its pediatric antimalarial to Zambia in collaboration with Malaria No More's Power of One campaign.

Baxter announces plans to split into two independent companies by mid-2015.

XstalBio Analytics' approach to vaccine analysis and formulation is aimed at understanding the antigen– adjuvant interaction.

FDA approves Xolair (omalizumab) for the treatment of a rare skin disease known as chronic idiopathic urticarial.